Innovating Works

HEARTOFSTROKE

Financiado
The heart of stroke Pipes Perfusion Parenchyma
My aim is to understand the cause of stroke in every single patient. Brain microinfarcts and macroinfarcts cause a major healthcare burden in Western societies both in terms of morbidity and costs. Cardiovascular thromboemboli fro... My aim is to understand the cause of stroke in every single patient. Brain microinfarcts and macroinfarcts cause a major healthcare burden in Western societies both in terms of morbidity and costs. Cardiovascular thromboemboli from the heart, aorta and neck arteries are considered as the main cause. Still, the vast majority of brain infarcts are unexplained. In contrast to the thromboembolic explanation for brain infarcts, heart infarcts are known to be caused by local atherosclerotic plaque of the coronary arteries and impaired perfusion. This has led to successful preventive and therapeutic strategies against myocardial infarction. For brain infarcts, a blind eye is turned to local atherosclerotic plaque in the intracranial vasculature (Pipes) and impaired Perfusion as possible causes of macro and microinfarcts (Parenchyma). For the ‘3Ps’ (Pipes, Perfusion, Parenchyma) I have created new research fields based on innovative noninvasive arterial spin labeling perfusion MRI, perfusion reserve, perfusion territory and vessel wall MRI methods. In this project, I will go an important step beyond the state of the art by investigating the total intracranial burden of disease of these ‘3Ps’ and systematic evaluations in patients. Pipes: novel methods to visualise and characterise intracranial plaque including inflammatory plaque enhancement, intraplaque haemorrhage and calcification detection. Perfusion: novel methods to investigate hemodynamic impairment in areas with critically low perfusion with noninvasive arterial spin labeling MRI methods and perfusion reserve methods specific for each intracranial perfusion territory. Parenchyma: novel methods to detect microinfarcts. Technical innovations (Pipes, Perfusion) will be applied in synergy to explain micro and macroinfarcts (Parenchyma). Patient specific biomarkers will, similar to the heart, pave the way for designing preventive and therapeutic strategies aimed at reducing the burden of neurodegenerative diseases. ver más
29/02/2020
UMC UTRECHT
1M€
Duración del proyecto: 60 meses Fecha Inicio: 2015-02-06
Fecha Fin: 2020-02-29

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2020-02-29
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-StG-2014: ERC Starting Grant
Cerrada hace 10 años
Presupuesto El presupuesto total del proyecto asciende a 1M€
Líder del proyecto
UNIVERSITAIR MEDISCH CENTRUM UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5